NTC Launches Imperial, the new eye drops product line on THE PATIENT'S SIDE

October 07, 2024 09:00 PM AEDT | By Cision
Follow us on Google News: https://kalkinemedia.com/resources/assets/public/images/google-news.webp

MILAN, Oct. 7, 2024 /PRNewswire/ -- NTC, an international pharmaceutical company headquartered in Milan, Italy, announced today to have embraced a strategic partnership with Silgan Dispensing Systems, a global leading supplier of dispensing solutions in healthcare to commercialize a set of new NTC proprietary eye drops with the innovative Silgan technology Iridya, a new preservative free multidose eye dropper.

Riccardo Carbucicchio
Riccardo Carbucicchio

"Thanks to Iridya, we improve our innovative dry eye portfolio, pursuing maximum patient satisfaction and compliance", says Marcello Selvaggio, NTC Global Head Ophthalmology. "We launched the Imperial product line for dry eye offering to our partners a solution that blends the benefits of the other main multidose preservative free devices into one, the Imperial product line, based on our innovative product range".

NTC is going to present the Imperial line during CPhI in Milan, supporting with evidence the innovation of this device characterized by exceptional drop control for precise dosing, elongated tip for a greater accuracy in instillation, and advanced ergonomics to assure a low squeeze force bottle.

"We are excited to unleash the potential of the Iridya technology of a leading company like Silgan," – says Riccardo Carbucicchio, CEO of NTC - "The NTC Imperial line is a further proof of NTC's focus on unmet medical needs and its continuous search for innovative solutions. The Imperial products will enhance the patient experience in dry eye and are designed to stay on the side of the patient".

"We are excited and proud to have partnered with NTC, a leading company in the ophthalmic market that has placed its trust in Silgan Dispensing Systems and our product Iridya™" - says Eric Demaris, Commercial Director EMEA Silgan Dispensing Healthcare. "We are certain that this collaboration will allow us to offer increasingly better solutions in the treatment of dry eye diseases based on Iridya preservative-free technology. Thanks to Iridya™ proven formula protection, broad compatibility, output accuracy and comfortable ergonomics, we can ensure brand owners deliver more secure dosing, drop after drop, to their patients."

NTC research makes innovation accessible to everyone and enhances product potential by looking at people's daily care needs and application habits.

The Imperial product line is a testimony to NTC's historical vocation for innovation to improve the experience and practice of care.

NTC offers products that increase people's participation and control, thus enhancing better compliance.

About NTC

A pharmaceutical company headquartered in Milan - Italy, with distributors and partners in more than 100 countries, engaged in research, development, registration, and commercialization of drugs, medical devices, and food supplements in ophthalmology, and other therapeutic areas including pediatrics, gynecology, and gastroenterology. NTC offers more than 200 partners innovative and highquality standard pharmaceutical products. For more information, please visit www.ntcpharma.com

About Silgan Dispensing Systems

Silgan Dispensing is a global leader in the design, development and distribution of highly engineered pumps and sprayers in the Home, Health and Beauty markets creating dispensing solutions for some of the world's most iconic brands.

 

 


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.

Two ASX Listed Stocks Giving Bullish Indications

Recent Articles

Investing Tips

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.